Approach to Suspected Drug Eruption

Introduction to Management

The British Journal of Dermatology recommends immediately discontinuing all suspected medications upon recognition of a drug eruption, as this is the cornerstone of management and directly impacts prognosis and mortality 1, 2, 3

Document the index date (when the first symptom or sign appeared) and track progression of the eruption daily, as recommended by the British Journal of Dermatology 2
Inquire about mucosal involvement, noting symptoms like dysuria or retention, as suggested by the British Journal of Dermatology 1, 2
Obtain a complete medication timeline covering the previous 2 months, including all prescription drugs, over-the-counter medications, and complementary/alternative therapies, as advised by the British Journal of Dermatology 1, 2, 3

Record baseline body weight, vital signs, and measure oxygen saturation with pulse oximeter, as recommended by the British Journal of Dermatology 2
Look for specific morphologic patterns, such as target lesions, purpuric macules, blisters, and areas of epidermal detachment, as suggested by the British Journal of Dermatology 2
Record extent of erythema and epidermal detachment separately on a body map using the Lund and Browder chart, as advised by the British Journal of Dermatology 1, 2

Perform full blood count, erythrocyte sedimentation rate, C-reactive protein, urea and electrolytes, magnesium, phosphate, bicarbonate, glucose, liver function tests, and coagulation studies, as recommended by the British Journal of Dermatology 1, 2
Consider Mycoplasma serology, particularly when causative drug cannot be identified, as suggested by the British Journal of Dermatology 1, 2

Discontinue any potential culprit drug immediately, as advised by the British Journal of Dermatology 1, 2, 3
Calculate SCORTEN within first 24 hours for severe cases to predict mortality risk, as recommended by Praxis Medical Insights 4, 5
Transfer patients with >10% BSA epidermal detachment to specialized burn unit or ICU, as suggested by Praxis Medical Insights 4
Apply topical moderate-to-high potency corticosteroids for mild/localized eruptions, as recommended by Praxis Medical Insights 3
Consider cyclosporine as potential treatment option under specialist supervision for severe cases, as suggested by Praxis Medical Insights 4, 5

Daily assessment of vital signs and organ function, as recommended by Praxis Medical Insights 4
Regular monitoring for infection, as suggested by Praxis Medical Insights 4
Daily review of mucosal sites to prevent complications, as advised by Praxis Medical Insights 4

Provide written information about drug(s) to avoid and encourage wearing MedicAlert bracelet, as recommended by Praxis Medical Insights 4, 5
Document drug allergy in patient's notes and inform all healthcare providers, as suggested by Praxis Medical Insights 4, 5
Report the episode to pharmacovigilance authorities, as advised by Praxis Medical Insights 4